Indegene Ltd reported a milestone FY26 with revenue at INR 3,510.5 crore, up 23.6%. Despite investments in AI and acquisitions impacting EBITDA, the company maintained strong cash flow and proposed a final dividend of INR 2.25 per share. Management targets 19-20% EBITDA margin by Q4 FY27.
Indegene Ltd Posts 23.6% Revenue Growth to INR 3,510.5 Crore in FY26
FY26 Revenue: INR 3,510.5 crore (23.6% Growth) FY26 PAT: INR 401.1 crore Reader Takeaway: Strong revenue growth driven by AI strategy; monitor margin recovery and acquisition integration. ## What just happened Indegene Ltd announced its financial results for Fiscal Year 2026, marking a significant year with revenue reaching INR 3,510.5 crore, a 23.6% increase over the previous year. The company's Profit After Tax (PAT) stood at INR 401.1 crore. Despite substantial investments in AI consulting, delivery platforms, and the integration of the BioPharm acquisition, EBITDA grew 11.1% to INR 624.7 crore. The company declared a final dividend of INR 2.25 per share. Indegene also ended the fiscal year with a robust net cash position of INR 1,481 crore. ## Why this matters The results highlight Indegene's focus on long-term, AI-led growth, even if it means short-term margin compression. The company's strategic shift towards becoming an 'Embedded Revenue Partner' by re-engineering end-to-end processes using GenAI is a key value driver. The sustained revenue growth, debt-free status, and strong cash reserves provide a stable base for future expansion and shareholder returns, demonstrated by the increased dividend. ## The backstory Indegene completed three acquisitions in FY26, with the largest being BioPharm in October 2025 for approximately INR 882 crore (USD 104 million). This acquisition bolstered its AI and digital advertising capabilities. The company has been actively embedding Generative AI (GenAI) across clinical, regulatory, and commercial workflows. The management had previously indicated that profitability absorbed significant investments in new offerings and integration costs. ## What changes now Indegene has set a target to achieve an EBITDA margin of 19%-20% by the fourth quarter of FY27. This recovery is expected as go-to-market investments normalize and larger outcome-based deals come online. The company has also expanded its client base, with active clients increasing to 91 and those contributing over USD 1 million in revenue growing to 53. ## Risks to watch Key watch points for investors include the timeline for margin normalization to the targeted 19-20% band by Q4 FY27, which depends on investment normalization and successful execution of outcome-based deals. The successful scaling and integration of its recent acquisitions, particularly BioPharm, remain critical execution dependencies. Additionally, investors should review the qualifications noted in the Secretarial Audit report, although the statutory auditors provided an unqualified opinion on financial statements. ## Peer comparison While specific peer financial data is not provided in the filing, Indegene operates in the life sciences and healthcare consulting sector, competing with global players focused on digital transformation and data analytics. Companies in this space often balance investment in new technologies like AI with profitability targets. ## Context metrics (time-bound) - FY26 Revenue: INR 3,510.5 crore (Growth: 23.6%) - FY26 EBITDA: INR 624.7 crore (Growth: 11.1%) - FY26 PAT: INR 401.1 crore - Final Dividend: INR 2.25 per share - Net Cash: INR 1,481 crore - Margin Target: 19%-20% EBITDA margin by Q4 FY27 - Active Clients: 91 (Increased) - Clients >USD 1M Revenue: 53 (Increased) ## What to track next Investors will be closely monitoring Indegene's progress towards its EBITDA margin targets in the upcoming quarters. The successful integration and revenue generation from recent acquisitions, particularly BioPharm, will be crucial. Tracking the growth of large client accounts and the continued embedding of AI solutions will also be key indicators of future performance.
